natgillin/translations-raw huggingface dataset:
The process according to claim 7 wherein the virus is a paramyxovirus or a recombinant paramyxovirus preferably selected among the group comprising measles virus, mumps virus, rubella virus, Sendai virus, Respiratory Syncythial virus (RSV), human para-influenza types I and III, Rinderpest virus, canine distemper virus, Newcastle disease virus, duck para-influenza virus. 
paramiksovirus ili rekombinantni paramiksovirus izabran iz grupe koja obuhvaća virus ospica, virus zaušnjaka, rubela virus, Sendai virus, Respiratorni Sincicijski virus (RSV), humani para-influenca tipovi I i III, virus goveđe kuge, virus pseće kuge, virus Newcastle bolesti, virus pačje para-influence;
A taste panel of 62 respondents composed of 50 % of men and 50 % of women, of which 31 % between 18 and 35 years old, 35 % between 36 and 50 years old, and 34 % older than 50 years, were asked to taste a cake with sugar and a cake with the sugar replacer, prepared according to the above mentioned recipe and procedure. 
Testirane su 62 osobe, od toga 50 % muškaraca i 50 % žena, 31 % u dobi od 18 do 35 godina, 35 % u dobi od 36 do 50 godina i 34 % starijih od 50 godina, koje su zamoljene da kušaju i kolač pripravljen sa šećerom i onaj sa zamjenom za šećer, pripravljen prema gore navedenom receptu i postupku.
The method according to claim 4, wherein the front-end decode operations are carried out in a first pass followed by a second pass, the first pass comprising unpacking metadata block-by-block and saving pointers to where the packed exponent and mantissa data are stored, and the second pass comprising using the saved pointers to the packed exponents and mantissa, and unpacking and decoding exponent and mantissa data channel-by-channel. 
Postupak prema zahtjevu 10, naznačen time da operacije dekodiranja u prednjem planu koje su izvedene u prvom prolazu prati drugi prolaz, gdje se prvi prolaz sastoji od raspakivanja metapodataka blok-po-blok i pohrane pokazivača koji ukazuju na mjesto skladištenja zapakiranih podataka eksponenta i mantise, te gdje se drugi prolaz sastoji od upotrebe pohranjenih pokazivača koji ukazuju na zapakirane eksponente i mantise i raspakivanja i dekodiranja podataka eksponenta i mantise kanal-po-kanal..
Particularly preferred is a fusion peptide, wherein component (II) is a peptide sequence containing a sequence according to SEQ ID No.: 22 (RRDFPEEVAI) or SEQ ID No.: 26 (AADFPEEVAI) (all peptide sequences given in the one-letter-code) or a sequence having at least 80% sequence homology with SEQ ID No.: 22 or with SEQ ID No.: 26. 
Fuzijski peptid prema patentnim zahtjevima 1 do 3, naznačen time da je komponenta (II) peptidna sekvenca koja sadrži sekvencu prema SEQ ID No.: 23 (RRDFPEEVAIVEEL) ili SEQ ID No. 24 (RRDFPEEVAIAEEL) ili sekvencu koja ima najmanje 80% identiteta sekvence sa SEQ ID No.: 23 ili 24.
The immunoconjugate of claim 13, wherein said antigen binding moiety is an immunoglobulin molecule, particularly an IgG molecule. 
SEK.: 19, a dio koji se veže na antigen je molekula imunoglobulina podrazreda IgG;-a koja je specifična za FAP.
The antibody of any of embodiments 19-21, wherein, said antibody comprises a heavy chain amino acid sequence comprising allelic variation, wherein said allelic variation is at least one or more positions selected from the group consisting of 214, 221, 356 and 358 as defined by the EU index numbering system. 
Protutijelo prema bilo kojem od zahtjeva 1-11, naznačeno time da, navedeno protutijelo sadrži sekvencu amino kiseline teškog lanca koja sadrži varijaciju alela, pri čemu je navedena varijacija alela barem jedan ili više položaja koji su odabrani iz skupine koja sadrži 214, 221, 356 1 358 kako je definirano sa sustavom označavanja EU indeksa.
A lectin protein according to claim 1, characterised by having at least one amino acid modification/substitution at one or more of the positions selected from 1, 14, 34, 113 and 123 of SEQ ID NO: 1; and having better solubility and stability properties as compared to the lectin of SEQ ID 1. 
Bjelančevina tipa lektin koja se sastoji od slijeda aminokiselina SEQ ID 2 ili 3, naznačena time da ima bolju topljivost i svojstva stabilnosti u usporedbi s lektinom od SEQ ID 1. Bjelančevina tipa lektin prema patentnom zahtjevu 1, naznačena time što navedeni lektin ima molekulsku masu približno 16,1 kDa i PI vrijednost od 6,614.
A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 1 and a therapeutically inert carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 17 i terapeutski inertan nosač.
Use of an immunostimulatory composition according to any of claims 1 to 6, or an adjuvant component, comprising or consisting of at least one mRNA, complexed with protamine, and at least one free mRNA, encoding at least one antigen, as defined according to any of claims 1 to 6, for preparing a pharmaceutical composition for prophylaxis, treatment, and/or amelioration of any of the diseases and disorders selected from cancers or tumor diseases, autoimmune diseases, infectious diseases, including viral, bacterial or protozoological infectious diseases or allergy or allergic diseases. 
Uporaba imunostimulacijskog pripravka prema bilo kojem zahtjevu od 1 do 16, ili komponenta adjuvanta, koja obuhvaća ili se sastoji od barem jedne (m)RNK, kompleksirane sa polikationskim spojem koji je polikationski peptid ili protein, te barem jedne slobodne mRNK, pri čemu barem jedna slobodna mRNK kodira barem jedan antigen, kako je definirano u bilo kojem zahtjevu od 1 do 12, naznačena time da je za pripravu farmaceutskog pripravka za profilaksu, liječenje i/ili ublažavanje bilo kojih bolesti i poremećaja koji su odabrani od karcinoma ili tumorskih bolesti, autoimunih bolesti, zarazne bolesti, uključujući virusne, bakterijske ili protozoološke zarazne bolesti ili alergije ili alergijske bolesti.
The seed of claim 12, wherein said AHAS-inhibiting herbicide comprises an imidazolinone herbicide, a sulfonylurea herbicide, a triazolopyrimidine herbicide, a sulfonylamino-carbonyltriazolinone herbicide, or a mixture of any of the foregoing. 
Sjeme biljke prema bilo kojem od zahtjeva 1 do 4 ili 6, naznačeno time, da se spomenuto sjeme tretira sa AHAS-inhibirajućim imidazolinon-herbicidom, ili mješavinom imidazolinon-herbicida, sulfonilurea-herbicida i/ili triazolopirimidin-herbicida.
At stage 4 of the method of FIG. 
Broj objave europskog patenta:
The placental stem cells for use according to claim 8, wherein said immune suppressor is cyclosporine A, 6-mercaptopurine, or azathioprine. 
Matične stanice posteljice za uporabu u skladu s patentnim zahtjevom 4, naznačenu time što je navedeni imunosni supresant ciklosporin A, 6-merkaptopurin ili azatioprin.
A product comprising (a) a PDE4 inhibitor as defined in any one of claims 1 and 3 to 6 and (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2, as a combined preparation for simultaneous, concurrent, separate or sequential use in the treatment of a patient suffering from or susceptible to a respiratory disease which responds to M3 antagonism. 
Proizvod koji sadrži (a) kortikosteroid kako je definiran u bilo kojem od patentnih zahtjeva 113 do 71 (b) antagonist M3 muskarinskih receptora kako je definiran u patentnom zahtjevu 1 ili 2, naznačen time, da je to proizvod u obliku kombiniranog pripravka za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u liječenju bolesnika koji su oboljeli ili bi mogli oboljeti od respiratorne bolesti kako je definirana u patentnom zahtjevu 11 ili 12.
adding an excess oxidant to the H3RuCl6 solution and stirring for 0.5-1.5 hours to completely oxidize the H3RuCl6 into H2RuCl6, adding excess NH4Cl to the H2RuCl6 solution, stirring the H2RuCl6 solution at 60-90° C. for 1-3 hours, filtering to obtain a filter cake, and washing the filter cake to obtain solid (NH4)2RuCl6; the oxidant used is a soluble chlorate; and reducing the solid (NH4)2RuCl6 at a temperature of 450-800° C. in a mixed atmosphere of hydrogen and nitrogen to obtain ruthenium; a volume fraction of the hydrogen in the mixed atmosphere of hydrogen and nitrogen is 1-15%. 
5) polako uvođenje suviška oksidansa u otopinu HsgRuC1l, miješanje otopine H3RuC14 tijekom 0.5-1.5 sati kako bi se potpuno oksidirala otopina H3RuCl da se dobije H2RuCL, uvođenje suviška NH,CI u otopinu H>RuCL, zagrijavanje otopine H,RuCL na 60-90?C, uz miješanje otopine H,RuC1; tijekom 1-3 sata, filtriranje otopine H,RuCL kako bi se dobilo filterski kolač, i ispiranje filtarskog kolača kako bi se dobila krutina (NH,)»RuC1, pri čemu je oksidans topljivi klorat; i 6) reduciranje krutine (NH,)pRuCL pri temperaturi od 450-800*C upotrebom plinovite smjese vodika i dušika kako bi se dobilo rutenij, pri čemu volumni udio vodika u plinskoj smjesi iznosi 1-15%.
A method for removal of fragments (30), according to claim 1, wherein said step of reducing or eliminating the electrostatic force (40, 40') is selected from the group comprised of: 
Postupak prema zahtjevu 1, naznačen time, da je navedeni korak promjene elektrostatske sile odabran iz skupine koja se sastoji od:
Metal structures, in particular C-shaped profiles, are known for supporting plasterboard or for forming shelves. 
Metalne konstrukcije, naročito C-oblikovani profili su poznati za nošenje ploča od gipsa ili za oblikovanje nosača za police.
a measurement unit for being attached to an anchor or an anchor rode (3), the measurement unit comprising: means for acquiring acceleration data, in particular an acceleration sensor, one or more auxiliary sensors; 
(a) mjernu jedinicu koja se pričvršćuje za sidro ili sidreni lanac (3), a koja mjerna jedinica sadrži: i sredstvo za dobivanje podataka o ubrzanju, osobito senzor ubrzanja, ii. = jedanili više pomoćnih senzora;
A container according to any preceding claim, wherein the lidding film is sealed thereto. 
Posuda prema bilo kojem od patentnih zahtjeva 1 do 9, pri čemu je tanki film pričvršćen.
88.46 As shown in table IV and FIG. 3, the main degradation product of the reference formulation, ET-701, was dramatically reduced when ET-743 was formulated in the presence of sucrose or lactose. 
Kao što je prikazano u tablici TV i na slici 3, glavni proizvod razgradnje kontrolnog oblika, ET-701, bio je prilično snižen kada je ET-743 oblikovan u prisutnosti saharoze ili laktoze.
A compound according to Formula (Ia): 
Spoj prema Formuli (Ia): pri čemu:
The use of a substantially cylindrical tube means that when the latter is being introduced into a hollow cavity with a blind end, such as the vagina, of which the wall is formed by muscle tissue, an tight closure is formed between this wall and the tube, i.e., in the case of the vagina, a closure is created in its deepest part, where the cervix from which the sample is to be taken is located. Because of the relatively large diameter also positioning in such a blind end is optimised. 
Upotreba uglavnom cilindrične cijevi znači da, kada se ova posljednja uvede u praznu šupljinu koja ima zatvoreni završetak, takvu šupljinu kao što je rodnica, čija stijenka je načinjena od mišićnog tkiva, tijesno se zatvori prostor između te stijenke i te cijevi, to jest u slučaju rodnice zatvoreni prostor se stvara na najdubljem dijelu gdje se nalazi grlić maternice iz kojega se treba uzeti uzorak, Zbog relativno velikog promjera također se optimira i pozicioniranje u takvom zatvorenom završetku.
The titled compound is prepared analogously to 4-fluoro-3-methoxy-benzenesulfonyl chloride (Intermediate 102a) by replacing 4-fluoro-3-methoxyaniline with 4-amino-2-ethoxy-benzonitrile. 
Naslovni spoj je proizveden analogno 4-fluor-3-metoksi-benzensulfonil kloridu (intermedđijat 1024) zamjenom 4-fluor-3-metoksianilina sa 4-amino-2-ctoksi-benzonitrilom.
The diphenyl sulfide derivative according to claim 4, or a pharmaceutically acceptable salt or hydrate thereof, wherein R1 represents a trifluoromethyl group, an alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms, an aryl group having 6 to 10 carbon atoms, or a benzyloxy group. 
Derivat difenil-sulfida u skladu s patentnim zahtjevom 4, ili njegova farmaceutski prihvatljiva sol ili hidrat, naznačen time što R1 predstavlja trifluormetilnu skupinu, alkilnu skupinu s 1 do 6 atoma ugljika, cikloalkilnu skupinu s 3 do 6 atoma ugljika, arilnu skupinu s 6 do 10 atoma ugljika ili benziloksi skupinu.
wherein in the step of combining the micro particles with the dermal matrix system, the micro particles are sprayed onto the dermal matrix system. The method for producing a dermal matrix system with micro particles according to claim 1, wherein the dipalmitoylphosphatidylcholine (DPPC) has a weight of 0.7-0.75 g, the resveratrol has a weight of 0.05-0.1 g and the alcohol has a volume of 350 mL. 
Postupak dobivanja dermalnog matriksa (10) u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u koraku pripravljanja smjese fosfolipida, antioksidacijskog sredstva i alkohola (122), gdje se 0,7-0,75 g dipalmitoilfosfatidilkolina (DPPC) i 0,05-0,1 g rezveratrola pomiješa u 350 ml alkohola, te ih se otopi.
Method according to any one of the preceding claims, characterized in that the step of measuring a tension value of the yarn (F) is executed by means of a tension sensor (4) associated upstream the bobbin (2). 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se korak mjerenja vrijednosti napetosti niti (F) provodi uz pomoć senzora napetosti (4), koji se nalazi uzvodno od kalema (2).
In some embodiments, the condition is a skin disease or disorder such as dermatitis, a thermal or chemical burn, a chronic wound, acne, alopecia, other disorders of the hair follicle, epidermolysis bullosa, sunburn, complications of sunburn, disorders of skin pigmentation, an aging-related skin condition; a post-surgical wound, a scar from a skin injury or burn, psoriasis, a dermatological manifestation of an autoimmune diseases or a graft-versus host disease, skin cancer; or a disorder involving hyperproliferation of skin cells. 
Farmaceutski pripravak za uporabu prema zahtjevu 31, naznačen time da je kožna bolest ili poremećaj dermatitis, toplinska ili kemijska opeklina, kronična rana, akne, alopecija, ostali poremećaji folikula kose, bulozna epidermoliza, opekline od sunca, komplikacije opeklina od sunca, poremećaj pigmentacije kože, stanje kože povezano sa starenjem, rana poslije operacije, ožiljak od ozljede kože ili opeklina, psorijaza, dermatološka manifestacija autoimune bolesti ili bolest presatka protiv domaćina, rak kože, poremećaj koji uključuje hiperproliferaciju stanica kože.
The pharmaceutical composition according to claim 1 or 2, comprising 0.5 15% w/V Vancomycin and N-acetyl-D-Alanine in a molar ratio of 1:1-1:40 and further comprising an amino acid. 
Farmaceutski pripravak prema zahtjevu 12 koji sadrži oko 0.5-15% w/V glikopeptidnog antibiotika i N-acetil-D-Alanin u molarnom omjeru od oko 1:1-1:40 koji ima pH od oko 3-6 i dalje sadrži aminokiselinu odabranu od Serina, Leucina, Valina, Lizina, Arginina i Ornitina.
System according to claim 1 comprising a connected device called “simple tap” or “two handles mixing tap” or “single handle mixing tap” comprising: a water inlet fitting for the “simple tap” or two water inlet fittings for the “single handle mixing tap” or “two handles mixing tap”. System according to claim 8 comprising for each water inlet of said called “simple tap” or “two handles mixing tap” or “single handle mixing tap” connected device a flowmeter of the flow rate supplying an electric signal of which at least one characteristics varies according to the flow rate circulating in the water inlet on which the sensor is connected. 
Sustav prema patentnom zahtjevu 1, koji sadrži slavinu, te se navedena slavina bira od jednostruke slavine, slavine miješalice s jednim upravljanjem ili slavine miješalice s dvostrukim upravljanjem, te navedena slavina sadrži: spojnicu za dovod vode za jednu slavinu ili dvije spojnice za ulaz vode (5A-2) za slavinu miješalice s jednim upravljanjem ili slavine miješalice s dvostrukim upravljanjem; i pri čemu za svaki od navedenih ulaza vode iz slavine, mjerač protoka (5C-5, 5D-5) za brzinu protoka proizvodi električni signal čija se najmanje jedna karakteristika mijenja u skladu s brzinom protoka koji struji u ulaz za vodu (5C-2, 5D-2) na koji je spojen senzor.
The pharmaceutical composition according to claim 19, wherein said inflammatory bowel disease is selected from the group consisting of Crohn's disease and ulcerative colitis. 
Farmaceutski pripravak za uporabu prema zahtjevu 18, gdje je navedena upalna bolest crijeva izabrana iz skupine koja se sastoji od Kronove bolesti i ulceroznog kolitisa.
The release profile of the active agent or the dissolution profile of the lozenge is governed by the matrix composition and lozenge size and can be varied according to the nature of the active agent and the desired effect. 
Profil oslobađanja aktivnog sredstva ili profil otapljanja tablete je reguliran kompozicijom matriksa i veličinom tablete 1 može varirati prema prirodi aktivnog sredstva i željenog efekta.
The compounds are furthermore suitable for treatment and/or prevention of disorders of bone density and structure such as but not restricted to osteoporosis, osteomalacia and hyperparathyroidism-related bone disorders. 
HR P20160285 T1 Lijek prema zahtjevu 8 ili 9 naznačen time da je za liječenje i/ili sprječavanje kardiovaskularnih, edematoznih i/ili upalnih poremećaja.
is one of the following: 
Broj objave europskog patenta:
The seal on the bottom of the base unit remains in place. 
Brtva na dnu osnovne jedinice ostaje na svom mjestu.
A compound of the invention for use in preventing or treating diseases mediated by a neo-angiogenesis process or associated with deregulated angiogenesis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof. 
Farmaceutski sastav, naznačen time, da obuhvaća terapeutski učinkovitu količinu spoja prema zahtjevu 1 ili 2, u kombinaciji s farmaceutski prihvatljivim pomoćnim sredstvom.
The compound for use according to Claim 5, wherein said additional therapeutic agent is selected from the group consisting of olanzapine and pimozide. 
Spoj za uporabu prema zahtjevu 5, naznačen time da se navedeno dodatno terapijsko sredstvo bira iz skupine koju čine olanzapin i pimozid.
The pharmaceutical composition of claim 3, wherein the composition is prepared for oral administration in combination with an additional therapeutic agent. 
Farmaceutski sastav za upotrebu prema zahtjevu 1 ili zahtjevu 2, gdje spomenuti postupak dalje obuhvaća davanje dodatnog terapeutskog sredstva.
thereby forming organic acid in the starting liquid; and removing at least 30% of anions generated in step c) from said liquid through an Anion Exchange Reverse Electro-Enhanced Dialysis (AX-REED) membrane stack while retaining at least 65% of said at least one micro-nutrient in said liquid, thereby obtaining an AX-REED liquid, said membrane stack comprising: 
uklanjanje najmanje 15 % organske kiseline nastale u koraku c) iz navedene tekućine uz zadržavanje najmanje 65 % navedene najmanje jedne mikro hranjive tvari u navedenoj tekućini, te se tako dobiva tekućina AX-REED, pri čemu se navedeni kiseli ion uklanja pomoću stoga membrana za anionsku izmjenu reverznom elektro poboljšanom dijalizom „Anion Exchange Reverse Electro-Enhanced Dialysis“ (AX-REED), navedeni stog membrana sadrži
The solid oral extended release pharmaceutical dosage form of anyone of claims 1, 3, 5 and 7, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month contains an amount of the at least one active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation that deviates no more than about 10 % points from the corresponding amount of active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation of a reference formulation prior to storage. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 16, naznačen time da formulacija matrice sa produljenim otpuštanjem nakon što je pohranjena na 25 *C 1 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca sadrži količinu od najmanje jednog aktivnog sredstva u % (težinski) vezano uz deklaracijski zahtjev aktivnog sredstva za formulaciju matrice s produljenim otpuštanjem tako da odstupanje nije veće od oko 10 % točaka u odnosu na odgovarajuću količinu aktivnog sredstva u % (težinski) relativno prema deklaracijskom zahtjevu aktivnog sredstva za formulaciju matrice s produljenim otpuštanjem referentne formulacije prije pohranjivanja.
Positioning in an orderly arrangement within a formwork a plurality of elements of said transparent to light material, 
Smještanje u ravnomjeran raspored unutar okvira više elemenata materijala koji propušta svjetlost,
the acetic acid concentration is 0.1 M, 
- < koncentracija octene kiseline je 0.1 M,
8, is aligned to the axis (14) of the peripheral wall (15) of the lid plate (2), whilst the grip portion (22) with its free end reaches out close to the inner face of the peripheral wall. 
Poklopac limenke u skladu s patentnim zahtjevom 3 ili 4, naznačen time što se prstenasta stijenka (11) pruža na dolje preko unutarnje površine (16) prstenastog nabora (15).
The method of claim 1, wherein the lipid:protein molar ratio in said starting suspension is from about 2:1 to about 200:1. The method of claim 1, further comprising the step of forming said starting suspension by a process comprising combining the lipid component and the protein component. 
Postupak prema bilo kojem od zahtjeva 1 do 10, naznačen time što nadalje sadrži, prije koraka (a), korak oblikovanja navedene početne suspenzije postupkom koji obuhvaća miješanje lipidne komponente i proteinske komponente.
applying a solution comprising poly (ethylene glycol) having a concentration of about 10% by weight and sorbitol having a concentration of from 5% to 20% by weight to the cation exchange chromatographic material, thereby separating the antibody of the IgG class in monomeric form from the antibody in aggregate form and obtaining the antibody in monomeric form. 
- proizvodnja protutijela IgG-razreda u monomernom obliku primjenom otopine koja sadrži poli(etilenglikol) i sorbitol na kromatografski materijal, te time desorbiranje / eluiranje protutijela IeG- razreda u monomernom obliku iz kromatografskog materijala, pri čemu poli(etilenglikol) ima koncentraciju od 10 masenih % i sorbitol ima koncentraciju od 5 masenih % do 20 masenih %.
A process according to claim 1, characterized in that, after the ultrafiltration step (4), it comprises an aerobic treatment in mesophilic conditions (7) and a gravity sedimentation treatment (8). 
Postupak prema zahtjevu 1, naznačen time, što nakon koraka ultrafiltracije (4), obuhvaća aerobnu obradu pod mezofilnim uvjetima (7) i obradu gravitacijskom sedimentacijom (8).
lubricating, if a lubricant is present, the dried granules and compressing it to obtain the core; and 
podmazivanja, ako je prisutno mazivo, osušenih granula, te njihovog komprimiranja kako bi se dobila HR P20140479 T1 jezgra; i e)